
- Vol 67 No 3
- Volume 67
- Issue 3
Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.
Articles in this issue
over 3 years ago
Delayed diagnosis of a bowel injury at laparoscopyover 3 years ago
Understanding abnormal uterine bleeding in adolescentsover 3 years ago
Adnexal torsion requires careful diagnosis, managementover 3 years ago
Bringing awareness to endometriosisover 3 years ago
Celebrating Laura E. Riley, MDover 3 years ago
Prenatal genetic data sharing and privacy risksalmost 4 years ago
Patient perspectives on vulvovaginal candidiasisalmost 4 years ago
Provider bias in contraceptive counselingNewsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
















